socaltech.com
San Diego-based
ViaCyte, a company which is using stem cell technology to develop treatments for Type 1 Diabetes, says it has raised $45M in an extension of its Series D funding round. The funding brings its Series D funding to more than $115M. The funding came from existing investors Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sander
The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please
login in order to access this members-only content, or